Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Phase 1/2 Suspended 30 enrolled Northwestern University Bristol-Myers Squibb · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating participants with diffuse large B-cell lymphoma.

Timeline

Start: 2018-11-20
Primary completion: 2024-12-11
Completion: 2025-06-11

Publications

Odetola O, Ma S, Winter J, Pro B, Roy I, Xie P, Zhang B, Chen Q, Koulogeorgas GP, Mi X, Chen R, Ma Y, Tang X, Bayer R, Eisner R, Nelson V, Shaikh H, Tsarwhas D, Saghir F, Venugopal P, Gordon LI, Karmali R. Nivolumab in combination with R-CHOP for treatment-naive diffuse large B-cell lymphoma: an evaluation of safety and efficacy. Blood Adv. 2025 Nov 11;9(21):5616-5625. doi: 10.1182/bloodadvances.2025016298.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	240 mg	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Doxorubicin	Other / unclassified	—	Intravenous
Background	Prednisone	Other / unclassified	—	Oral
Background	Rituximab	Monoclonal antibody	—	Intravenous
Background	Vincristine	Small molecule	—	Intravenous

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications